In Vivo Imaging of Effector Cells in Anti-Lymphoma Therapy
- Determine the number of indium In 111-labeled peripheral blood mononuclear cells
(PBMCs) and indium In 111-labeled polymorphonuclear leukocytes (PMNLs) trafficking into
lymphoma tumors prior to therapy in patients with non-Hodgkin's lymphoma.
- Compare the number of PBMC and PMNL trafficking prior to vs after therapy in these
- Compare, preliminarily, the number of in vivo baseline (i.e., pre-therapy) trafficking
of PBMCs vs PMNLs in these patients.
- Gather important data regarding the inter- and intra-patient variability of effector
cell trafficking into these tumors.
- Assess the relationship between response at 8-12 weeks and the magnitude of baseline
effector cell trafficking or the magnitude of post-rituximab effector cell trafficking
in these patients.
OUTLINE: This is a multicenter study. Patients are assigned to 1 of 2 groups.
- Group I: Patients receive autologous indium In 111 (^111In)-labeled peripheral blood
mononuclear cells on day 0.
- Group II: Patients receive autologous ^111In-labeled polymorphonuclear leukocytes on
In both groups, patients undergo blood collection on day 0. Patients then undergo full-body
single-photon emission-computed tomography (SPECT) scan 4 hours after cell infusion and on
day 2. The labeling and imaging process may be repeated after at least 1 course of
Cellular uptake is measured by reader/visual interpretation, a semiquantitative grading
system, and tumor-to-background uptake ratios.
PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study.
Number of baseline indium In 111-labeled peripheral blood mononuclear cells (PBMCs) trafficking into tumors
Gregory Wiseman, MD
|Mayo Clinic Cancer Center||Rochester, Minnesota 55905|
|Holden Comprehensive Cancer Center at University of Iowa||Iowa City, Iowa 52242-1002|